Details for Patent: 11,666,590
✉ Email this page to a colleague
Which drugs does patent 11,666,590 protect, and when does it expire?
Patent 11,666,590 protects JARDIANCE and is included in one NDA.
This patent has thirty-two patent family members in twenty-three countries.
Drugs Protected by US Patent 11,666,590
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | JARDIANCE | empagliflozin | TABLET;ORAL | 204629-001 | Aug 1, 2014 | RX | Yes | No | 11,666,590 | ⤷ Subscribe | TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,666,590
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014255727 | ⤷ Subscribe | |||
| Australia | 2019253791 | ⤷ Subscribe | |||
| Canada | 2909728 | ⤷ Subscribe | |||
| Canada | 3175715 | ⤷ Subscribe | |||
| Chile | 2015003022 | ⤷ Subscribe | |||
| China | 105377266 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
